What Now ?This is not time to panic and sell your shares for nothing.
Firstly by today's trading activity the market baked in a Replicel loss of the Arbitration and has peged it's current value at $.10. Let's hope so.
Metzger is right there is a reason that Shiseido fought hard to retain this technology in Asia. I would assume now that they have the green light they will pursue commercialization of this hair treatment. If they do it will obviously bring value to Replicel holding the rights to the treatment for the rest of the world. In fact Shiseido may now make an offer to Replicel for those rights.
It is now time for Mainpointe to step up and honor their contract and get the Dermal Injector FDA Approval. Replicel should now quickly put all available resources toward finding a North American manufacturer of the device.
Now that we have this "cloud" which has been sitting over this company for the past 2 years lifted it is time for the management to get back to communicating with the shareholders. I well crafted update would be very timely right about now.